BLA 761363 · Merck Sharp Dohme
Winrevair
Sotatercept-Csrk · Injection
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Mar 26, 2024: To treat pulmonary arterial hypertension
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 26, 2024
Approved uses
3
Original approval plus efficacy supplements
Registered trials
40
6 Phase 3, 8 recruiting
FAERS reports
6,188
3,495 serious, 286 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 21, 2026.
WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization (WHO) functional class (FC), and reduce the risk of clinical worsening events including hospitalization for PAH, lung transplantation and death [see Clinical Studies (14.1) ] . WINREVAIR is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class (FC), and reduce the risk of clinical worsening events, including hospitalization for PAH, lung transplantation and death. ( 1 )
Mechanism: Sotatercept-csrk, a recombinant activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, is an activin signaling inhibitor that binds to activin A and other TGF- β superfamily ligands. As a result, sotatercept-csrk improves the balance between the pro-proliferative (ActRIIA/Smad2/3-mediated) and anti-proliferative (BMPRII/Smad1/5/8-mediated) signaling to modulate vascular proliferation. In rat models of PAH, a sotatercept-csrk analog reduced inflammation and inhibited proliferation of endothelial and smooth muscle cells in diseased vasculature. These cellular changes were associated with...
Therapeutic areas: Cardiovascular and metabolic · Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 21, 2026 Supplement 12 · Efficacy OrphanLetterLabel
- Oct 24, 2025 Supplement 7 · Efficacy · priority review OrphanLetter
- Mar 26, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- WINREVAIR · SOTATERCEPT-CSRK 60MG · INJECTABLE, INJECTION · Prescription
- WINREVAIR · SOTATERCEPT-CSRK 45MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sotatercept" as an intervention, any sponsor and status, largest first.
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07218029 · 815 participants (planned) · Start May 12, 2021 · Primary completion Dec 7, 2028
Drug: Sotatercept · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; Tucson, Arizona · 137 sites in all
- Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023)Pivotal-lookingActive, not recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06814145 · 440 participants (planned) · Start Apr 16, 2025 · Primary completion Aug 10, 2035
Drug: Sotatercept · For: Hypertension, Pulmonary
Sites: Phoenix, Arizona; La Jolla, California; Santa Barbara, California · 57 sites in all
- A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07839585 · 352 participants (planned) · Start Nov 26, 2026 · Primary completion Jan 8, 2030
Drug: Sotatercept; Placebo · For: Pulmonary Hypertension
- A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)Pivotal-lookingCompleted
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
NCT04576988 · 324 participants · Start Jan 25, 2021 · Primary completion Aug 26, 2022
Drug: Sotatercept; Placebo and 1 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Tucson, Arizona; San Diego, California · 120 sites in all
- Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)Pivotal-lookingTerminated
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
NCT04811092 · 321 participants · Start Mar 18, 2022 · Primary completion Apr 3, 2025
Drug: Sotatercept · For: Pulmonary Arterial Hypertension
Sites: Scottsdale, Arizona; Tucson, Arizona; La Jolla, California · 152 sites in all
- A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)Pivotal-lookingCompleted
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
NCT04896008 · 173 participants · Start Dec 1, 2021 · Primary completion Jul 26, 2024
Drug: Sotatercept · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 57 sites in all
- A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)Pivotal-lookingCompleted
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USAIndustry
NCT04945460 · 165 participants · Start Dec 29, 2021 · Primary completion Sep 5, 2025
Drug: Sotatercept 0.3 mg/kg; Placebo and 1 more · For: Hypertension, Pulmonary
Sites: Phoenix, Arizona; Tucson, Arizona; La Jolla, California · 119 sites in all
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06664801 · 164 participants · Start Nov 14, 2024 · Primary completion Nov 20, 2025
Drug: Sotatercept; Background PAH Therapy · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Aurora, Colorado; Indianapolis, Indiana · 98 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache826
- dyspnoea698
- diarrhoea639
- fatigue548
- epistaxis537
- nausea507
- dizziness504
- haemoglobin increased315
- cough275
- dyspnoea exertional274
- vomiting256
- product dose omission issue253
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 40 |
| 2024 | 782 |
| 2025 | 2,268 |
| 2026 | 3,092 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Winrevair (Sotatercept-Csrk)
2024 spending
$178M
Beneficiaries
1,923
10,663 claims
Per beneficiary
$92,367
$16,651.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $177,621,008 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
Hoeper MM, Badesch DB, Ghofrani HA, et al. · N Engl J Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death.
Humbert M, McLaughlin VV, Badesch DB, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sotatercept for the Treatment of Pulmonary Arterial Hypertension.
Humbert M, McLaughlin V, Gibbs JSR, et al. · N Engl J Med 2021 · Clinical Trial, Phase II, Multicenter Study
- Sotatercept for Pulmonary Arterial Hypertension within the First Year after Diagnosis.
McLaughlin VV, Hoeper MM, Badesch DB, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension.
Humbert M, McLaughlin V, Gibbs JSR, et al. · Eur Respir J 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Efficacy and safety of sotatercept in pulmonary arterial hypertension: a meta-analysis of randomized controlled trials.
Ershed M, da Silva ABN, Felix de Farias Dos Santos AC, et al. · Expert Rev Respir Med 2025 · Meta-Analysis, Systematic Review
Sponsor: Merck & Co.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.